Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Two-Antibody combo outsmart advanced cancer?

NCT ID NCT03495882

Completed Disease control Sponsor: Agenus Inc. Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether combining two experimental immunotherapy drugs, zalifrelimab and balstilimab, can help shrink or control advanced solid tumors, including cervical cancer. The drugs are designed to block different 'brakes' on the immune system, potentially allowing it to attack cancer more effectively. The study includes adults with locally advanced, recurrent, or metastatic solid tumors who have exhausted standard treatment options. Researchers are evaluating safety, tolerability, and how well the combination works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Two experimental immunotherapy drugs given together: zalifrelimab (AGEN1884) and balstilimab (AGEN2034), designed to help the immune system attack cancer cells.
What this could lead to
If this combination works, it could offer a new treatment option for people with advanced cervical cancer or other solid tumors that have stopped responding to standard therapy.
What could go wrong
This is an early-stage trial, so the combination may not be effective or may cause significant side effects. Results are not yet known, and more research is needed before this could become a standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER

Contacts and locations

Locations

  • ARENSIA Exploratory Medicine Unit, Institute of Oncology

    Chisinau, 2025, Moldova

  • Augusta University

    Augusta, Georgia, 30912, United States

  • BRCR Medical Center, Inc

    Plantation, Florida, 33322, United States

  • Bacs-Kiskun Megyei Korhaz

    Kecskemét, 6000, Hungary

  • BioResearch Group SP. Z O.O.

    Nadarzyn, 05-830, Poland

  • CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU

    Dnipro, 49102, Ukraine

  • CI Transcarpathian Cl Onc Center Dep of Surgery #1 SHEI Ivano-Frankivsk NMU

    Ivano-Frankivsk, 76018, Ukraine

  • CI of Healthcare Regional Clinical Specialized Dispensary of the Radiation Protection, Department of Surgery

    Kharkiv, 61166, Ukraine

  • Cancer Treatment Centers of America

    Zion, Illinois, 60099, United States

  • Centrum Onkologii-Instytut im.M.Sklodowskiej Curie

    Warsaw, 02-781, Poland

  • Chattanooga's Program In Women's Oncology

    Chattanooga, Tennessee, 37403, United States

  • City of Hope National Medical Center

    Duarte, California, 91010, United States

  • CliniCore International

    Baytown, Texas, 77521, United States

  • Clinica Universidad de Navarra

    Pamplona, 31008, Spain

  • Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda.

    São Paulo, 01317, Brazil

  • Communal Non-profit Enterprise Regional Center of Oncology

    Kharkiv, 61070, Ukraine

  • Comprehensive Care and Research Center

    Goodyear, Arizona, 85338, United States

  • Debreceni Egyetem

    Debrecen, 4032, Hungary

  • Hospital Universitari i Politecnic La Fe

    Valencia, 46026, Spain

  • Hospital Universitario La Paz

    Madrid, 28046, Spain

  • Hospital Universitario Virgen Macarena

    Seville, 41009, Spain

  • IBCC - Instituto Brasileiro de Controle do Câncer

    São Paulo, 03102, Brazil

  • ICO l'Hospitalet - Hospital Duran i Reynals

    L'Hospitalet de Llobregat, 8908, Spain

  • Icon Cancer Care South Brisbane

    South Brisbane, Australia

  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet

    Szolnok, 5004, Hungary

  • Khmelnytskyi Regional Oncological Dispensary

    Khmelnytskyi, 29000, Ukraine

  • Kyiv Сity Clinical Oncological Center

    Kyiv, 03115, Ukraine

  • LLC Arensia Exploratory Medicine

    Tbilisi, 0112, Georgia

  • Limited Liability Company Adonis

    Kyiv, 08114, Ukraine

  • Linear Clinical Research

    Perth, Western Australia, 6009, Australia

  • Magyar Honvedseg Egeszsegugyi Kozpont

    Budapest, 1062, Hungary

  • Mater Research

    South Brisbane, 4101, Australia

  • Medical Center Oncolife

    Kyiv, 04078, Ukraine

  • Medical Clinic Innovacia, LLC

    Kiev, 07352, Ukraine

  • Ochsner Cancer Institute

    New Orleans, Louisiana, 70121, United States

  • Orszagos Onkologiai Intezet

    Budapest, 1122, Hungary

  • Pecsi Tudomanyegyetem

    Pécs, 7624, Hungary

  • Providence Regional Cancer System

    Aberdeen, Washington, 98520, United States

  • START Madrid. Oncology Phase I

    Madrid, 28040, Spain

  • Scientia Clinical Research

    Sydney, Australia

  • Swedish Cancer Institute

    Seattle, Washington, 98104, United States

  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont

    Szeged, 6720, Hungary

  • Treatment-Prevention Institution Volyn Regional Oncological Dispensary

    Lutsk, 43018, Ukraine

  • University of Miami

    Miami, Florida, 33136, United States

  • University of Oklahoma

    Oklahoma City, Oklahoma, 73104, United States

  • West Michigan Cancer Center

    Kalamazoo, Michigan, 49007, United States

  • Zala Megyei Szent Rafael Korhaz

    Zalaegerszeg, 8900, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.